Colorectal Neoplasms
Conditions
Keywords
Low-dose aspirin,, Cancer prevention
Brief summary
The study evaluates the protective effect of low-dose aspirin use on gastrointestinal cancers (colorectal, esophageal and gastric cancers) in long-term users, episodic users and non-users of aspirin in Taiwan.
Detailed description
The primary objective is to investigate the protective effect of long-term low dose use of aspirin on colorectal, esophageal and gastric cancer in adult subjects from Taiwan. Secondary objectives are to evaluate the protective effect by duration of low-dose aspirin use on colorectal cancer, the effect of discontinuation of aspirin on colorectal cancer prevention, the staging distribution of colorectal cancer and the description of fatal cases due to colorectal cancer. Aspirin use will be identified through Taiwanese National Health Insurance (NIH) data from 2000 to 2015. Cancer cases and staging of the three cancer types will be ascertained through the Taiwan Cancer Registry, using data from 2000 to 2014. Fatal cases will be ascertained using Mortality database from 2000 to 2015.
Interventions
Low dose of aspirin, i.e. \< 150 mg daily
OTHERNo drug
Non-consumers
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age 40 or older at the cohort entry date. * Taiwanese National Health Insurance enrollees with non-missing and consistent age and gender information.
Exclusion criteria
* Subjects with any cancer diagnosis before cohort entry date. * No use of National Health Insurance before the cohort entry date. * Low dose aspirin prescription before cohort entry date. * Subjects with conditions contra-indicated for low dose aspirin use before cohort entry date.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of subjects with colorectal cancer | Up to 14 years | Number of subjects with colorectal cancer for each cohort (long-term, episodic and former users of aspirin, and non-users). |
| Number of subjects with esophageal cancer | Up to 14 years | Number of subjects with esophageal cancer for each cohort (long-term, episodic and former users of aspirin, and non-users). |
| Number of subjects with gastric cancer | Up to 14 years | Number of subjects with gastric cancer for each cohort (long-term, episodic and former users of aspirin, and non-users). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of aspirin use to colorectal cancer | Up to 14 years | The duration of low-dose aspirin use in years to colorectal cancer. |
| Number of fatal cases due to colorectal cancer | Up to 14 years | Derived from Taiwan Mortality database. |
| Time from aspirin discontinuation to colorectal cancer | Up to 14 years | Period of time in years from discontinuation of aspirin use to detection of colorectal cancer. |
| Stage of colorectal cancer | Up to 14 years | The stage of cancer will be determined according to the International Classification of Diseases for Oncology (ICD-O-3). |
Countries
Taiwan
Outcome results
None listed